Philip Reilly

Interleukin Genetics, Inc. engages in the marketing and development of proprietary genetic tests for chronic inflammatory diseases and health-related conditions focuses on metabolism and inflammation. The company was founded in 1986 and is headquartered in Waltham, MA.

Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA.

Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA.

Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA.

Stellular Bio, Inc. develops technology to produce independent human platelets from human induced pluripotent stem cells. The company was founded by Jonathan Thon, Joseph Italiano and Sven Karlsson in 2014 and is headquartered in Watertown, MA.

Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts.